What question did this study set out to answer?

The study aims to investigate if CPAP effectively reduces daytime sleepiness in patients with hypermobile Ehlers-Danlos syndrome and obstructive sleep apnea.

July 10, 2026Open Access

Obstructive sleep apnea and CPAP efficacy in patients with Hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorder: a case-control study

Key Points

The study aims to investigate if CPAP effectively reduces daytime sleepiness in patients with hypermobile Ehlers-Danlos syndrome and obstructive sleep apnea.
Retrospective review from 2020 to 2024 at a single institution.
68 cases of hEDS/HSD with OSA matched with 68 controls based on demographics.
Data analyzed from polysomnogram, sleep clinic consults, and Epworth Sleepiness Scale assessments.
Cases had lower sleep efficiency (77% vs. 82%, p < 0.05) and higher insomnia prevalence (44.7% vs. 34.3%, p < 0.05).
CPAP reduced ESS significantly in controls (−4.46, p < 0.05) but not in cases (−1.56, p > 0.05).
Cases used nasal masks less frequently (22.6% vs. 41.5%, p < 0.05).

Abstract

Abstract Purpose Hypermobile Ehlers-Danlos syndrome (hEDS) and Hypermobility Spectrum Disorder (HSD) are hereditary tissue disorders existing on a spectrum associated with insomnia and obstructive sleep apnea (OSA). Oropharyngeal abnormalities in hEDS/HSD may exacerbate OSA; this study investigates if continuous positive airway pressure (CPAP) adequately decreases daytime sleepiness in hEDS/HSD patients with OSA. Methods A single institution retrospective review was conducted from 2020 to 2024. Adults with hEDS/HSD and OSA (cases) were matched based on sex, age, race, and body mass index (BMI) to adults with OSA (controls). Data from polysomnogram (PSG), sleep clinic consults, and reevaluation 3–9 months post-CPAP were analyzed. The Epworth Sleepiness Scale (ESS) was used to assess daytime sleepiness. Results 68 cases (47% hEDS/53% HSD, Beighton score 5.71 ± 2.29, age 34.07 ± 13.28, BMI 32.88 ± 8.47) were matched to 68 controls. All pairs completed PSG; 53 pairs pursued CPAP; 41 pairs were reevaluated. Cases had lower sleep efficiency (77%±16% vs. 82%±10%, p 0.05). CPAP reduced ESS in controls (− 4.46, p 0.05). Cases and controls had similar CPAP compliance (75.6%±25.2% vs. 74.6%±26.7%, p > 0.05), Apnea-Hypopnea Index (AHI) (7.2 13.6 vs. 7.0 12.7, p > 0.05), lowest SpO 2 (86.08% ± 4.31% vs. 85.67% ± 3.52%, p > 0.05), and residual AHI (1.55 1.75 vs. 1.2 1.35, p > 0.05). Cases used nasal masks less frequently (22.6% vs. 41.5%, p < 0.05). Conclusion CPAP was not associated with a statistically significant improvement in daytime sleepiness in hEDS/HSD patients despite effective treatment, suggesting that hypermobility-related factors beyond OSA may contribute to residual sleepiness.

Ask AI

Helpful

Bookmark

View Full Paper